The drug discovery and development firm is to establish a 74,000 sq ft drug development facility at Alderley Park, Cheshire, bringing together three subsidiary businesses onto one site.
The company has reached an agreement with Manchester Science Partnerships, which will see Alderley Park become the new home for Redx Oncology.
The business develops anti-cancer drugs and is currently based within the Royal Liverpool Hospital’s Duncan Building, which is due to be demolished in 2017.
The Redx group already has two other subsidiaries, Redx Anti-Infectives and Redx Immunology based at Alderley Park in 37,000 sq.ft. of laboratory and office space.
The Redx Pharma move will be completed by the end of the year and will see all 193 Redx staff operate on the same site for the first time, with all 88 Liverpool jobs relocating.
Neil Murray, chief executive of Redx Pharma, said: “Bringing our three teams together will support our ambitious growth plans and give the business some valuable human, scientific and logistical synergies.
“Alderley Park’s high specification laboratories and superlative facilities present a commercially attractive solution as we seek to provide the best infrastructure and environment for our staff. The £30m capital investment that has been committed to the site over the next three years is impressive indeed. It will create one of the most important multi-occupier sites for life science in Europe.”
Alderley Park is 400-acres and was formerly occupied by AstraZeneca. The park is owned by MSP, a Manchester-based public-private partnership and the UK’s largest science park operator. MSP’s shareholders are Bruntwood, University of Manchester, Manchester Metropolitan University, Central Manchester University Hospitals NHS Foundation Trust and Manchester, Cheshire East and Salford City Councils.